Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: NPH insulin and regular insulin Clear all
Completed Phase 3 Interventional Results available

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

NCT00694122
View directory record Official record
Conditions
Type 1 Diabetes, Dawn Phenomenon
Interventions
Lantus (glargine)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes

NCT00678080
View directory record Official record
Conditions
Pregnancy Complications
Interventions
Metformin, Insulin (NPH and Regular)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Brownsville, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

NCT00835861
View directory record Official record
Conditions
Non Insulin Dependent Diabetes, Pregnancy
Interventions
Metformin, Insulin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

Inpatient Diabetes on Corticosteroids

NCT01970241
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
NPH, Correction Factor
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

NCT01790438
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2605541, Human Insulin NPH, Oral Antihyperglycemic Medications (OAM)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Tempe, Arizona • Concord, California • Fresno, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Sep 17, 2026, 5:31 AM EDT
Recruiting Phase 4 Interventional

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

NCT06445946
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
24
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy

NCT00574405
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200)
Drug · Device
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
8 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

NCT00279201
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 79 Years
Enrollment
2,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
138
States / cities
Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2011 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects

NCT01358435
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
30% Regular Insulin Human Neutral and 70%Isophane Insulin, Novolin 70/30
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

NCT00993473
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 6 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population

NCT00071448
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin human, insulin lispro, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 18 Years
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 4 Interventional

Insulin Therapy in the Hospital Comparing Two Protocols

NCT00841919
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glargine insulin, NPH insulin and regular insulin, lispro insulin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2009 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

A Clinical Trial to Prevent New Onset Diabetes After Transplantation

NCT01683331
View directory record Official record
Conditions
Prevention of New Onset Diabetes Among Kidney Transplant Patients
Interventions
Insulin treatment for hyperglycemia
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes

NCT01662921
View directory record Official record
Conditions
Diabetes During Pregnancy
Interventions
NPH, Insulin LISPRO, Insulin glulisine
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 4 Interventional

Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)

NCT05922033
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions
Patient-led Insulin (intervention group), Provider-led Insulin (standard care)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 17, 2026, 5:31 AM EDT
Not listed No phase listed Observational

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

NCT04034524
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GLP-1 receptor agonist, Insulin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 17, 2026, 5:31 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

NCT01963728
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin, Isophane, insulin glargine
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 4 Interventional

Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients

NCT00174824
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 70 Years
Enrollment
1,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2009 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy

NCT03620890
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Neutral Protamine Hagedorn (NPH), Detemir insulin
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

NCT02302716
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, LANTUS®, Oral Antihyperglycemic Medication
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Sep 17, 2026, 5:31 AM EDT
Recruiting Phase 3 Interventional

RCT Glargine vs NPH for Treatment of DM in Pregnancy

NCT06619301
View directory record Official record
Conditions
Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
Interventions
Insulin glargine, insulin NPH
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 17, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients

NCT00645827
View directory record Official record
Conditions
Glucose, Blood
Interventions
IICE Dosing, Healthcare Provider dosing
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2014 · Synced Sep 17, 2026, 5:31 AM EDT